Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Research analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a research note issued to investors on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($0.35) per share for the quarter, down from their prior forecast of ($0.19). HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals' Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.38) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.01) EPS and FY2026 earnings at $0.03 EPS.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The firm had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million.
A number of other equities analysts also recently issued reports on the stock. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a "hold" rating for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th.
Read Our Latest Analysis on Vanda Pharmaceuticals
Vanda Pharmaceuticals Stock Performance
VNDA traded down $0.12 on Friday, hitting $4.33. 228,802 shares of the company were exchanged, compared to its average volume of 721,190. Vanda Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $6.75. The firm has a fifty day simple moving average of $4.42 and a two-hundred day simple moving average of $4.63. The stock has a market capitalization of $254.89 million, a PE ratio of -13.52 and a beta of 0.69.
Insiders Place Their Bets
In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the stock in a transaction on Friday, February 28th. The shares were bought at an average price of $4.76 per share, with a total value of $47,600.00. Following the purchase, the chief executive officer now directly owns 2,361,730 shares in the company, valued at $11,241,834.80. This trade represents a 0.43% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders bought 52,000 shares of company stock valued at $235,580. 8.90% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in VNDA. Price T Rowe Associates Inc. MD increased its holdings in Vanda Pharmaceuticals by 17.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock valued at $107,000 after purchasing an additional 3,370 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Vanda Pharmaceuticals by 32.4% in the fourth quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 4,599 shares in the last quarter. Brandywine Global Investment Management LLC lifted its position in Vanda Pharmaceuticals by 13.9% in the fourth quarter. Brandywine Global Investment Management LLC now owns 39,390 shares of the biopharmaceutical company's stock valued at $189,000 after acquiring an additional 4,820 shares during the last quarter. MetLife Investment Management LLC increased its position in Vanda Pharmaceuticals by 18.9% during the first quarter. MetLife Investment Management LLC now owns 32,816 shares of the biopharmaceutical company's stock worth $151,000 after buying an additional 5,210 shares during the period. Finally, SG Americas Securities LLC increased its holdings in shares of Vanda Pharmaceuticals by 26.8% in the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock valued at $124,000 after acquiring an additional 5,459 shares during the period. 88.14% of the stock is currently owned by hedge funds and other institutional investors.
About Vanda Pharmaceuticals
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Stories
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
